Correction: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

@inproceedings{Bailey2013CorrectionDA,
  title={Correction: Dapagliflozin add-on to metformin in type 2 diabetes inadequately
controlled with metformin: a randomized, double-blind, placebo-controlled 102-week
trial},
  author={Clifford J Bailey and Jorge Luiz Gross and Delphine Hennicken and Nayyar Iqbal and Traci A. Mansfield and J. F. Van Der List},
  booktitle={BMC medicine},
  year={2013}
}
BACKGROUND Management of type 2 diabetes with metformin often does not provide adequate glycemic control, thereby necessitating add-on treatment. In a 24-week clinical trial, dapagliflozin, an investigational sodium glucose cotransporter 2 inhibitor, improved glycemic control in patients inadequately controlled with metformin. The present study is an extension that was undertaken to evaluate dapagliflozin as long-term therapy in this population. METHODS This was a long-term extension (total… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 85 extracted citations

Durability of response to dapagliflozin: a review of long-term efficacy and safety.

Current medical research and opinion • 2017
View 8 Excerpts
Highly Influenced

DPP-4 Inhibitors vs . SGLT-2 Inhibitors ; Cons and Pros

Xourgia E, Ak, Melidonis
2017
View 7 Excerpts
Highly Influenced

Dapagliflozin in patients with type 2 diabetes mellitus.

Therapeutic advances in endocrinology and metabolism • 2015
View 3 Excerpts
Highly Influenced

Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis

Diabetes therapy : research, treatment and education of diabetes and related disorders • 2018
View 2 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Dapagliflozin add - on to metformin in type 2 diabetes inadequately controlled with metformin : a randomized , double - blind , placebo - controlled 102 - week trial

CJ Bailey, JL Gross, +3 authors JF List
BMC Medicine • 2013

Similar Papers

Loading similar papers…